Analyst Ratings For Keryx Biopharmaceuticals (NASDAQ:KERX)
Today, Morgan Stanley lowered its price target on Keryx Biopharmaceuticals (NASDAQ:KERX) to $6.00 per share.
Some recent analyst ratings include
- 7/25/2017-Cowen Reiterated Rating of Market Perform.
- 1/11/2017-Citigroup Upgrade from a “Sell ” rating to a ” Neutral” rating.
- 11/19/2016-FBR & Co Reiterated Rating of Hold.
- 9/8/2016-JMP Securities Reiterated Rating of Outperform.
Recent Insider Trading Activity For Keryx Biopharmaceuticals (NASDAQ:KERX)
Keryx Biopharmaceuticals (NASDAQ:KERX) has insider ownership of 2.58% and institutional ownership of 65.22%.
- On 1/29/2018 Brian Adams, General Counsel, sold 1,541 with an average share price of $4.81 per share and the total transaction amounting to $7,412.21.
- On 1/29/2018 Scott A. Holmes, CFO, sold 2,830 with an average share price of $4.81 per share and the total transaction amounting to $13,612.30.
- On 1/23/2018 John F. Neylan, Insider, sold 1,322 with an average share price of $4.92 per share and the total transaction amounting to $6,504.24.
- On 1/18/2018 Christine A. Carberry, COO, sold 9,048 with an average share price of $4.87 per share and the total transaction amounting to $44,063.76.
- On 1/5/2018 Brian Adams, General Counsel, sold 753 with an average share price of $4.69 per share and the total transaction amounting to $3,531.57.
- On 1/5/2018 Greg Madison, CEO, sold 1,067 with an average share price of $4.69 per share and the total transaction amounting to $5,004.23.
- On 10/30/2017 Brian Adams, General Counsel, sold 1,405 with an average share price of $6.03 per share and the total transaction amounting to $8,472.15.
Recent Trading Activity for Keryx Biopharmaceuticals (NASDAQ:KERX)
Shares of Keryx Biopharmaceuticals closed the previous trading session at 4.37 up +0.17 4.05% with 1028257 shares trading hands.